Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 249

1.

Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-naïve patients with advanced HIV infection.

Manosuthi W, Sungkanuparph S, Vibhagool A, Rattanasiri S, Thakkinstian A.

HIV Med. 2004 Mar;5(2):105-9.

PMID:
15012650
[PubMed - indexed for MEDLINE]
2.

Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naïve patients: a cohort study.

Keiser P, Nassar N, White C, Koen G, Moreno S.

HIV Clin Trials. 2002 Jul-Aug;3(4):296-303.

PMID:
12187503
[PubMed - indexed for MEDLINE]
3.

Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study).

Pulido F, Arribas JR, Miró JM, Costa MA, González J, Rubio R, Peña JM, Torralba M, Lonca M, Lorenzo A, Cepeda C, Vázquez JJ, Gatell JM; EfaVIP Cohort Study Group.

J Acquir Immune Defic Syndr. 2004 Apr 1;35(4):343-50.

PMID:
15097150
[PubMed - indexed for MEDLINE]
4.

Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.

Lapphra K, Vanprapar N, Chearskul S, Phongsamart W, Chearskul P, Prasitsuebsai W, Chokephaibulkit K.

Int J Infect Dis. 2008 Nov;12(6):e33-8. doi: 10.1016/j.ijid.2007.10.008. Epub 2008 Jun 24.

PMID:
18573672
[PubMed - indexed for MEDLINE]
Free Article
5.

Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin.

Manosuthi W, Mankatitham W, Lueangniyomkul A, Chimsuntorn S, Sungkanuparph S.

HIV Med. 2008 May;9(5):294-9. doi: 10.1111/j.1468-1293.2008.00563.x.

PMID:
18400076
[PubMed - indexed for MEDLINE]
6.

Nevirapine versus efavirenz based antiretroviral treatment in naive Indian patients: comparison of effectiveness in clinical cohort.

Patel AK, Pujari S, Patel K, Patel J, Shah N, Patel B, Gupte N.

J Assoc Physicians India. 2006 Dec;54:915-8.

PMID:
17334006
[PubMed - indexed for MEDLINE]
7.

Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.

Abgrall S, Yeni PG, Bouchaud O, Costagliola D; Clinical Epidemiology Group from the French Hospital Database on HIV.

AIDS. 2006 Oct 24;20(16):2099-106.

PMID:
17053356
[PubMed - indexed for MEDLINE]
8.

The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART.

van Leth F, Andrews S, Grinsztejn B, Wilkins E, Lazanas MK, Lange JM, Montaner J; 2NN study group.

AIDS. 2005 Mar 25;19(5):463-71.

PMID:
15764851
[PubMed - indexed for MEDLINE]
9.

Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.

Bannister WP, Ruiz L, Cozzi-Lepri A, Mocroft A, Kirk O, Staszewski S, Loveday C, Karlsson A, Monforte Ad, Clotet B, Lundgren JD; EuroSIDA study group.

AIDS. 2008 Jan 30;22(3):367-76. doi: 10.1097/QAD.0b013e3282f3cc35.

PMID:
18195563
[PubMed - indexed for MEDLINE]
10.

Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1-infected persons.

van den Berg-Wolf M, Hullsiek KH, Peng G, Kozal MJ, Novak RM, Chen L, Crane LR, Macarthur RD; CPCRA 058 Study Team, the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA), and The International Network for Strategic Initiative in Global HIV Trials (INSIGHT).

HIV Clin Trials. 2008 Sep-Oct;9(5):324-36. doi: 10.1310/hct0905-324.

PMID:
18977721
[PubMed - indexed for MEDLINE]
11.

Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.

Chiesa E, Bini T, Adorni F, Capetti A, Rizzardini G, Faggion I, Mussini C, Sollima S, Melzi S, Bongiovanni M, Tordato F, Cicconi P, Castelnuovo B, Rusconi S, d'Arminio Monforte A.

Antivir Ther. 2003 Feb;8(1):27-35.

PMID:
12713061
[PubMed - indexed for MEDLINE]
12.

Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial.

Swaminathan S, Padmapriyadarsini C, Venkatesan P, Narendran G, Ramesh Kumar S, Iliayas S, Menon PA, Selvaraju S, Pooranagangadevi NP, Bhavani PK, Ponnuraja C, Dilip M, Ramachandran R.

Clin Infect Dis. 2011 Oct;53(7):716-24. doi: 10.1093/cid/cir447.

PMID:
21890776
[PubMed - indexed for MEDLINE]
Free Article
13.

Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults.

Nachega JB, Hislop M, Dowdy DW, Gallant JE, Chaisson RE, Regensberg L, Maartens G.

AIDS. 2008 Oct 18;22(16):2117-25. doi: 10.1097/QAD.0b013e328310407e.

PMID:
18832875
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Differential CD4 T-cell response in HIV-1-infected patients using protease inhibitor-based or nevirapine-based highly active antiretroviral therapy.

van Leth F, Wit FW, Reiss P, Schattenkerk JK, van der Ende ME, Schneider MM, Mulder JW, Frissen PH, de Wolf F, Lange JM.

HIV Med. 2004 Mar;5(2):74-81.

PMID:
15012645
[PubMed - indexed for MEDLINE]
15.

Virological and immunological responses of efavirenz-based HAART regimen initiated in HIV-infected patients at CD4 < 100 versus CD4 > or = 100 cells/mm3.

Kiertiburanakul S, Sungkanuparph S, Rattanasiri S, Manosuthi W, Vibhagool A, Thakkinstian A.

J Med Assoc Thai. 2006 Sep;89(9):1381-7.

PMID:
17100373
[PubMed - indexed for MEDLINE]
16.

Nevirapine plus efavirenz plus didanosine: a simple, safe, and effective once-daily regimen for patients with HIV infection.

Jordan WC, Jefferson R, Yemofio F, Tolbert L, Conlon V, Carroll H, Green DC, Green A, Green R.

J Natl Med Assoc. 2003 Dec;95(12):1152-7.

PMID:
14717471
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Comparative durability of nevirapine versus efavirenz in first-line regimens during the first year of initiating antiretroviral therapy among Swaziland HIV-infected adults.

Takuva S, Evans D, Zuma K, Okello V, Louwagie G.

Pan Afr Med J. 2013 May 3;15:5. doi: 10.11604/pamj.2013.15.5.1889. Print 2013.

PMID:
23847702
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

First-line highly active antiretroviral regimens in 2001-2002 in the French Hospital Database on HIV: combination prescribed and biological outcomes.

Potard V, Rey D, Mokhtari S, Frixon-Marin V, Pradier C, Rozenbaum W, Brun-Vezinet F, Costagliola D; French Hospital Database on HIV, ANRS C04.

Antivir Ther. 2007;12(3):317-24.

PMID:
17591021
[PubMed - indexed for MEDLINE]
19.

SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open-label study in HIV-infected naive individuals.

Núñez M, Soriano V, Martín-Carbonero L, Barrios A, Barreiro P, Blanco F, García-Benayas T, González-Lahoz J.

HIV Clin Trials. 2002 May-Jun;3(3):186-94.

PMID:
12032877
[PubMed - indexed for MEDLINE]
20.

Nevirapine or efavirenz combined with two nucleoside reverse transcriptase inhibitors compared to HAART: a meta-analysis of randomized clinical trials.

Torre D, Tambini R, Speranza F.

HIV Clin Trials. 2001 Mar-Apr;2(2):113-21.

PMID:
11590519
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk